Indivior Pharmaceuticals, Inc. Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent
Indivior Pharmaceuticals, Inc. (INDV) reported Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent of $1.00 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent · last filed 2026-08-03
- Indivior Pharmaceuticals, Inc. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2026-06-30 was $1.00M, a 50.00% decline year-over-year.
- Indivior Pharmaceuticals, Inc. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2026-03-31 was $0.00, a 100.00% decline year-over-year.
- Indivior Pharmaceuticals, Inc. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2025-12-31 was $3.00M.
- Indivior Pharmaceuticals, Inc. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2025-09-30 was $0.00, a 100.00% decline year-over-year.
- Indivior Pharmaceuticals, Inc. other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2025 was $6.00M.
- Indivior Pharmaceuticals, Inc. other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2024 was -$6.00M, a 400.00% decline from fiscal 2023.
- Indivior Pharmaceuticals, Inc. other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2023 was $2.00M.
- Indivior Pharmaceuticals, Inc. other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2022 was -$6.00M.
| Period end | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 3 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 6 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 9 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.00M 10-Q · filed 2026-08-03 | $1.00M 10-Q · filed 2026-08-03 | $4.00M derived: sum of 3 quarters · filed 2026-08-03 | $4.00M derived: sum of 4 quarters · filed 2026-08-03 |
| 2026-03-31 | $0.00 10-Q · filed 2026-08-03 | $3.00M derived: sum of 2 quarters · filed 2026-08-03 | $3.00M derived: sum of 3 quarters · filed 2026-08-03 | $5.00M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-12-31 | $3.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $3.00M derived: sum of 2 quarters · filed 2026-02-26 | $5.00M derived: sum of 3 quarters · filed 2026-08-03 | $6.00M 10-K · filed 2026-02-26 |
| 2025-09-30 | $0.00 10-Q · filed 2025-10-30 | $2.00M derived: sum of 2 quarters · filed 2026-08-03 | $3.00M 10-Q · filed 2025-10-30 | -$8.00M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-06-30 | $2.00M 10-Q · filed 2026-08-03 | $3.00M 10-Q · filed 2026-08-03 | -$8.00M derived: sum of 3 quarters · filed 2026-08-03 | -$1.00M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-03-31 | $1.00M 10-Q · filed 2026-08-03 | -$10.00M derived: sum of 2 quarters · filed 2026-08-03 | -$3.00M derived: sum of 3 quarters · filed 2026-08-03 | -$3.00M derived: sum of 4 quarters · filed 2026-08-03 |
| 2024-12-31 | -$11.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$4.00M derived: sum of 2 quarters · filed 2026-02-26 | -$4.00M derived: sum of 3 quarters · filed 2026-02-26 | -$6.00M 10-K · filed 2026-02-26 |
| 2024-09-30 | $7.00M 10-Q · filed 2025-10-30 | $7.00M derived: sum of 2 quarters · filed 2025-10-30 | $5.00M 10-Q · filed 2025-10-30 | |
| 2024-06-30 | $0.00 10-Q · filed 2025-07-31 | -$2.00M 10-Q · filed 2025-07-31 | ||
| 2024-03-31 | -$3.00M 10-Q · filed 2025-10-30 | |||
| 2023-12-31 | $2.00M 10-K · filed 2026-02-26 | |||
| 2022-12-31 | -$6.00M 10-K · filed 2025-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |